The CRLF2 Breakapart probe consists of a red 243kb probe, which is centromeric to the CRLF2 gene, and two green probes (71kb, 131kb), which are telomeric to CRLF2.
Overexpression of Cytokine Receptor-Like Factor 2 (CRLF2) has been shown to occur in Acute Lymphoblastic Leukaemia (ALL), particularly that associated with Down Syndrome (DS-ALL)1,2.
Overexpression of this protein has been associated with activation of the JAK/STAT5 pathway in transduced primary B-cell progenitors1,3 and various groups have attempted to characterise the biochemical consequences of these genetic lesions, with the goal of identifying targets for new therapies2,3.
CRLF2 overexpression has been shown to be caused by chromosomal rearrangements including the t(X;14) or t(Y;14) translocations or interstitial deletions of the pseudoautosomal region 1 (PAR1) of chromosomes X and Y. These place CRLF2 under control of an IGH enhancer1 or juxtapose the first non-coding exon of P2RY8 to the coding region of CRLF22, respectively. All of these CRLF2 rearrangements are cytogenetically cryptic and cannot be detected by conventional G-banded analysis1, making FISH a powerful detection tool for these abnormalities and an aid to furthering this research. Our CRLF2 Breakapart probe will detect rearrangements of the CRLF2 gene, whilst the P2RY8 Deletion probe allows detection of deletions between CRLF2 and P2RY8, causing the fusion gene.
The quality of the products we have received from CytoCell have been excellent. The FISH probes they provide to us give intense, strong signals and are a pleasure to count. What has really stood out however has been the level of support and assistance provided by CytoCell’s application specialists. The team worked very closely alongside our own during the adoption of this product and spent many hours with us perfecting the technique, going above and beyond what I would expect during the transition period. Source BioScience absolutely demand high quality products and service to be able to deliver our results with confidence, and that is what we have received from CytoCell.
Laboratory Operations Manager, Source BioScience, UK